Novartis assumed with a Buy at Jefferies. Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space “as it enters a period of sustained earnings momentum.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.